CAR T-Cell Therapy

Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.

With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.

In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed what community oncologists should keep in mind when treating patients who are viable for CAR T-cell therapy.

In a retrospective analysis of 115 patients with relapsed/refractory multiple myeloma who progressed after therapy on a bispecific antibody, researchers found that the myeloma patients can be salvaged with sequential T-cell redirection therapy.

The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.

Patients with relapsed or refractory multiple myeloma who relapsed after treatment with B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy.

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.

Peter A. McSweeney, MD, discusses challenges with implementing chimeric antigen receptorT-cell therapy in some community oncology practices.

Treatment with CD30 chimeric antigen receptor T-cell therapy combined with a monoclonal antibody has begun in the phase 1b ACTION study of patients with relapsed or refractory classical Hodgkin lymphoma.

Nicolas Gazeau discusses a retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who have received chimeric antigen receptor T-cell therapy.

Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables.

Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.

The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer.

Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.

Bruce Feinberg, DO, discusses a survey researching chimeric antigen receptor T-cell therapy’s growing usage by community oncologists for diffuse large B-cell lymphoma.

Manali Kamdar, MD, discusses data from the 2 clinical trials that supported the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

The FDA has granted approval lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma, with specific indications for patients with relapsed or refractory disease.

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.

In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.

Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.

Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.